Chemotherapy-induced anemia in solid cancer;L'anemia indotta dalla chemioterapia nei tumori solidi

Recenti Progressi in Medicina

Volumn 93, Issue 11, 2002, Pages 585-601

  Stasi, Roberto ^a   Abriani, Luca ^a   Beccaglia, Patrizia ^a   Terzoli, Edmondo ^a   Amadori, Sergio ^a  

^a REGINA APOSTOLORUM HOSPITAL   (Italy)

Author keywords

Anemia; Bladder cancer; Breast cancer; Chemotherapy; Colorectal cancer; Fatigue; Non small cell lung cancer; Ovarian cancer; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HEMOGLOBIN; IRINOTECAN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; RALTITREXED; RECOMBINANT ERYTHROPOIETIN; TOPOTECAN; UFT; VINBLASTINE;

ANEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; DISEASE SEVERITY; FATIGUE; HUMAN; INCIDENCE; QUALITY OF LIFE; REVIEW; SOLID TUMOR; SYMPTOMATOLOGY; WELLBEING; CHEMICALLY INDUCED DISORDER; HOSPITALIZATION; NEOPLASM;

ANEMIA; ANTINEOPLASTIC AGENTS; ERYTHROPOIETIN, RECOMBINANT; HUMANS; INCIDENCE; NEOPLASMS; SEVERITY OF ILLNESS INDEX;

EID: 0036846437     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Dalton JD, Bailey NP, Barrett-Lee PJ, O'Brien MER. Multicenter UK audit of anemia in patients receiving cytotoxic chemotherapy. Proc ASCO 1998; 17: 418a (abstract).
2. Kaye SB, Lewis CR, Paul J, et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992; 340: 329-33.
3. Ardizzoni A, Venturini M, Crinò L, et al. High doseintensity chemotherapy with accelerated cyclophosphamide-doxorubicin-etoposide and granulocytemacrophage colony-stimulating factor, in the treatment of small-cell lung cancer. Eur J Cancer 1993; 29A: 687-92.
4. Steward WP, von Pawel J, Gatzemeier U, et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: A prospective randomized study of 3000 patients. J Clin Oncol 1998; 16: 642-650.
5. Thatcher N. Controlled study of the efficacy and safety of recombinant human erythropoietin in the prevention of anaemia in patients with small cell lung cancer receiving chemotherapy. Ann Oncol 1994; 5 (suppl 8): 89.
6. Schiller JH, Kim K, Hutson P, et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial. J Clin Oncol 1996; 14: 2345-52.
7. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997; 15: 2090-6.
8. Okamoto H, Saijo N, Shinakai T, et al. Chemotherapy-induced anemia in patients with primary lung cancer. Ann Oncol 1992; 3: 819-24.
9. Abets R. Erythropoietin for anemia in cancer patients. Eur J Cancer 1993; 29A (suppl 2): 2-8.
10. Ludwig H, Sundal E, Pecherstorfer M, et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1995; 76: 2319-29.
11. Dunphy FR, Dunleavy TL, Harrison BR, et al. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Cancer 1997; 79: 1623-8.
12. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 1998; 16: 3412-25.
13. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15: 1218-34.
14. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875-82.
15. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13: 63-74.
16. Cleeland CS. Identifying hemoglobin level for optimal quality of life: Results of an incremental analysis. Proc Am Soc Clin Oncol 18: 2215, 1999 (abstract)
17. Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ. Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 1997; 15: 744-9.
18. Comella P. Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer. Semin Oncol 2001; 28 (suppl 7): 7-10.
19. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18: 122-30.
20. von Pawel J, Wagner H, Niederle N, et al. Paclitaxel and cisplatin advanced non-small cell lung cancer. Semin Oncol 1996; 23: 7-9.
21. Gatzemeier U, von Pawel J, Gottfried M, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18: 3390-9.
22. 2) plus carboplatin in non-small cell lung cancer: A randomized study. Semin Oncol 1997; 24 (suppl 12): 30-3.
23. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol 1995; 13: 1860-70.
24. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced nonsmall cell lung cancer: A Southwest Oncology Group Study. J Clin Oncol 1998; 16: 2459-65.
25. Kosmas C, Tsavaris N, Panopoulos C, et al. Gemcitabine and vinorelbine as second-line therapy in non-small cell lung cancer after prior treatment with taxane+platinum-based regimens. Eur J Cancer 2001; 37: 972-8.
26. Laack E, Mende T, Benk J, et al. Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: A phase II trial. Eur J Cancer 2001; 37: 583-90.
27. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small cell lung cancer: A randomized multicenter trial. Lancet 2001; 357: 1478-84.
28. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995; 75: 968-72.
29. Francis PA, Rigas JR, Kris MG, et al. Phase II trial of docetaxel in patients with stage III and IV nonsmall cell lung cancer. J Clin Oncol 1994; 12: 1232-7.
30. Fossella FV, Lee JS, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic nonsmall-cell lung cancer. J Clin Oncol 1994; 12: 1238-44.
31. Shepherd FA, Abratt R, Crinò L, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-103.
32. Anderson H, Lund B, Bach F, et al. Single agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 1994; 12: 1821-6.
33. Gatzemeier U, Shepherd FA, Le Chevalier T, et al. Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study. Eur J Cancer 1996; 32A: 243-8.
34. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993; 85: 384-8.
35. Ranson MR, Jayson G, Perkins S, Anderson H, Thatcher N. Single-agent paclitaxel in advanced non-small cell lung cancer: Single-center phase II study using a 3-hour administration schedule. Semin Oncol 1997; 24 (suppl 12): 6-9.
36. Millward MJ, Bishop JF, Friedlander M, et al. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced nonsmall-cell lung cancer. J Clin Oncol 1996; 14: 142-8.
37. O'Rourke M, Crawford J, Schiller J, et al. Survival advantage for patients with stage IV NSCLC treated with single agent Navelbine® in a randomized controlled trial. Proc ASCO 1993; 12: 343 (abstract).
38. nd, Hollis DR, et al. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: A randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1995; 13: 1871-9.
39. Hainsworth JD, Levitan N, Wampler GL, et al. Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of smallcell lung cancer. J Clin Oncol 1995; 13: 1436-42.
40. Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994; 5: 601-7.
41. Pujol JL, von Pawel J, Tumolo S, et al. Etoposide plus cisplatin with or without the combination of 4-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: A French Federation of Cancer Institutes Multicenter phase III randomized study. J Natl Cancer Inst 2001; 93: 300-8.
42. Luikart SD, Goutsou M, Mitchell ED, et al. Phase I/II trial of etoposide and carboplatin in extensive smallcell lung cancer. A report from the Cancer and Leukemia Group B. Am J Clin Oncol 1993; 16: 127-31.
43. Figueredo AT, Hryniuk WM, et al. Cotrimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 1985; 3: 54-64.
44. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17: 658-67.
45. Thomas P, Castelnau O, Paillotin D, et al. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: A Groupe Français de Pneumo-Cancérologie Study. J Clin Oncol 2001; 19: 1320-5.
46. Gridelli C, Manzione L, Perrone F, et al. Carboplatin plus paclitaxel in extensive small cell lung cancer: A multicentre phase 2 study. Br J Cancer 2001; 84: 38-41.
47. Hainsworth JD, Gray JR, Strup SL, et al. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: Comparison of sequential phase II trials using different dose-intensities. J Clin Oncol 1997; 15: 3464-70.
48. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 1995; 13: 1430-5.
49. Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer 1994; 30A: 1058-60.
50. Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe CH, et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer 1993; 29A: 1720-2.
51. Furuse K, Kubota K, Kawahara M, et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. Oncology 1996; 53: 169-72.
52. Pritchard KI, Paterson AH, Fine S, et al. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: A report of the National cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997; 15: 2302-11.
53. Stewart DJ, Evans WK, Shepherd FA, et al. Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: Superiority of doxorubicin. J Clin Oncol 1997; 15: 1897-905.
54. Michelotti A, Venturini M, Tibaldi C, et al. Single agent epirubicin as first line chemotherapy for metastatic breast cancer. Breast Cancer Res Treat 2000; 59: 133-9.
55. Norris B, Pritchard KI, James K, et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 2000; 18: 2385-94.
56. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-54.
57. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444-54.
58. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial. J Clin Oncol 2001; 19: 1707-15.
59. Aisner J, Cirrincione C, Perloff M, et al. Combination chemotherapy for metastatic or recurrent carcinoma of the breast - A randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. J Clin Oncol 1995; 13: 1443-52.
60. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-Year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19: 602-11.
61. Del Mastro L, Venturini M, Lionetto R, et al. Accelerated-Intensified Cyclophosphamide, Epirubicin, and Fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: Results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ovest-Mammella Inter Gruppo Group. J Clin Oncol 2001; 19: 2213-21.
62. Powles TJ, Jones AL, Judson IR, Hardy JR, Ashley SE. A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. Br J Cancer 1991; 64: 406-10.
63. Pagani O, Sessa C, Nole F, et al. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase III study. Ann Oncol 2000; 11: 985-91.
64. Milla-Santos A, Milla L, Rallo L, Solano V. Highdose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer. Am J Clin Oncol 2001; 24: 138-42.
65. Nisticò C, Garufi C, Barni S, et al. Phase II study of epirubicin and vinorelbine with granulocyte colonystimulating factor: A high activity, dose-dense weekly regimen for advanced breast cancer. Ann Oncol 1999; 10: 937-42.
66. Degardin M, Bonneterre J, Hecquet B, et al. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994; 5: 423-6.
67. Jones S, Winer E, Vogel C, et al. Randomized comparison of vinorelbine and melphalan in anthracycline refractory advanced breast cancer. J Clin Oncol 1995; 13: 2567-74.
68. Corfu-A Study Group. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 1995; 13: 921-8.
69. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-92.
70. Cocconi G, Cunningham D, Van Cutsem E, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol 1998; 16: 2943-52.
71. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
72. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a randomised multicentre trial. Lancet 2000; 355: 1041-7.
73. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-60.
74. Gonzalez Baron M, Feliu J, Garcia Giron C, et al. UFT modulated with leucovorin in advanced colorectal cancer: Oncopaz experience. Oncology 1997; 54 (suppl 1): 24-9.
75. Sanchiz F, Milla A. Tegafur-uracil (UFT) plus folinic acid in advanced rectal cancer. Jpn J Clin Oncol 1994; 24: 322-6.
76. Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study. J Clin Oncol 2000; 18: 1337-45.
77. Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000; 18: 3084-92.
78. Conte PF, Bruzzone M, Chiara S, et al. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. J Clin Oncol 1986; 4:965-71.
79. Papadimitriou CA, Moulopoulos LA, Vlahos G, et al. Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma long term results of a phase II study. Cancer 2000; 89: 1547-54.
80. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183-93.
81. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 1996; 14: 3056-61.
82. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-22.
83. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66.
84. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol 2001; 19: 1901-5.
85. Kavanagh JJ, Kudelka AP, de Leon CG, et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 1996; 2: 837-42.
86. Piccart MJ, Gore M, Ten Bokkel Huinink W, et al. Docetaxel: An active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995; 87: 676-81.
87. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-77.
88. Bajetta E, Chiara Stani S, De Candis D, et al. Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer. A phase II trial. Cancer 2000; 89: 763-8.